Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.10.10.681723

Macrophage efferocytosis is controlled by epigenetic modifications mediated by RBPJ

Abstract

Efferocytosis, phagocytic clearance of apoptotic cells, is crucial for inflammation resolution and maintenance of tissue homeostasis. However, it is not known how epigenetic alterations govern macrophage-mediated efferocytosis. A Cleavage Under Targets and Release Using Nuclease (CUT&RUN) sequencing revealed a genome-wide selective suppression of H3K9me3, a heterochromatin mark that represses gene activity, in macrophages undergoing efferocytosis. Moreover, Recombination Signal Binding Protein for Immunoglobulin Kappa J region (RBPJ), which is a transcription factor typically involved in the canonical Notch signaling process, dampened this epigenetic modification, enhanced apoptotic cell clearance, and suppressed inflammation by mouse atherosclerotic plaque, alveolar, peritoneal, and bone marrow-derived macrophages and human primary macrophages. Inhibition of the Notch signaling in macrophages significantly reduced efferocytosis whereas activation of this signaling augmented apoptotic debris clearance. Mechanistically, RBPJ upregulated Stard13 and Arsg by diminishing H3K9me3 on their promoters. Stard13 promoted efferocytosis by magnifying actin polymerization via inhibition and activation of Rho and RAC GTPases, respectively. Genetic and pharmacological inhibitions of SUV39H1/H2, the methyltransferases that are responsible for H3K9 trimethylation, amplified the expression of Stard13 and Arsg, and augmented efferocytosis by RBPJ-/- macrophages. In sum, this study shows epigenetic regulation of efferocytosis in tissue macrophages.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dutta, P., Sadaf, S., Zhang, X., Lei, L., Jixing, S., Jamal, I., Modugu, G.. 2025-10-12. Macrophage efferocytosis is controlled by epigenetic modifications mediated by RBPJ. https://doi.org/10.1101/2025.10.10.681723

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗